In the past week, GILD stock has gone up by 3.31%, with a monthly gain of 14.62% and a quarterly plunge of -4.01%. The volatility ratio for the week is 0.93%, and the volatility levels for the last 30 days are 2.31% for Gilead Sciences, Inc The simple moving average for the past 20 days is 4.91% for GILD’s stock, with a 16.67% simple moving average for the past 200 days.
Is It Worth Investing in Gilead Sciences, Inc (NASDAQ: GILD) Right Now?
Gilead Sciences, Inc (NASDAQ: GILD) has a higher price-to-earnings ratio of 23.66x compared to its average ratio. GILD has 36-month beta value of 0.31. Analysts have mixed views on the stock, with 15 analysts rating it as a “buy,” 4 as “overweight,” 11 as “hold,” and 0 as “sell.”
The public float for GILD is 1.24B, and currently, short sellers hold a 1.99% ratio of that float. The average trading volume of GILD on June 09, 2025 was 9.56M shares.
GILD) stock’s latest price update
Gilead Sciences, Inc (NASDAQ: GILD)’s stock price has increased by 0.05 compared to its previous closing price of 112.46. However, the company has seen a 3.31% increase in its stock price over the last five trading sessions. benzinga.com reported 2025-06-05 that In February, the U.S. Food and Drug Administration (FDA) accepted Gilead Sciences, Inc.’s GILD New Drug Application (NDA) submissions for lenacapavir — the company’s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis (PrEP).
Analysts’ Opinion of GILD
Many brokerage firms have already submitted their reports for GILD stocks, with Cantor Fitzgerald repeating the rating for GILD by listing it as a “Overweight.” The predicted price for GILD in the upcoming period, according to Cantor Fitzgerald is $125 based on the research report published on April 22, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see GILD reach a price target of $132, previously predicting the price at $115. The rating they have provided for GILD stocks is “Outperform” according to the report published on March 04th, 2025.
Deutsche Bank gave a rating of “Buy” to GILD, setting the target price at $120 in the report published on February 18th of the current year.
GILD Trading at 6.22% from the 50-Day Moving Average
After a stumble in the market that brought GILD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.21% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at GILD starting from O’Day Daniel Patrick, who sale 10,000 shares at the price of $110.42 back on May 30 ’25. After this action, O’Day Daniel Patrick now owns 620,268 shares of Gilead Sciences, Inc, valued at $1,104,193 using the latest closing price.
DANIEL O’DAY, the Officer of Gilead Sciences, Inc, proposed sale 10,000 shares at $110.42 during a trade that took place back on May 30 ’25, which means that DANIEL O’DAY is holding shares at $1,104,192 based on the most recent closing price.
Stock Fundamentals for GILD
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 0.78 for the gross margin
The net margin for Gilead Sciences, Inc stands at 0.21. The total capital return value is set at 0.19. Equity return is now at value 32.51, with 10.58 for asset returns.
Based on Gilead Sciences, Inc (GILD), the company’s capital structure generated 0.57 points at debt to capital in total, while cash flow to debt ratio is standing at 0.42. The debt to equity ratio resting at 1.3. The interest coverage ratio of the stock is 8.35.
Currently, EBITDA for the company is 4.43 billion with net debt to EBITDA at 1.61. When we switch over and look at the enterprise to sales, we see a ratio of 5.47. The receivables turnover for the company is 6.55for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.37.
Conclusion
To put it simply, Gilead Sciences, Inc (GILD) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
